Loading
A phase 2 trial of Domvanalimab, Zimberelimab, Carboplatin in non-small-cell lung cancer, run by Arcus Biosciences, Inc., now completed.
Study Evaluating Effectiveness and Safety of Zimberelimab and Domvanalimab in Lung Cancer is a phase 2 interventional study registered as NCT04736173 by Arcus Biosciences, Inc., with 169 participants enrolled, started 2021-02-08 and reached its primary completion in 2026-09-17. Interventions recorded: Domvanalimab, Zimberelimab, Carboplatin, Paclitaxel, Pemetrexed. Conditions listed: Non Small Cell Lung Cancer, Nonsquamous Non Small Cell Lung Cancer, Squamous Non Small Cell Lung Cancer, Lung Cancer. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Domvanalimab, Zimberelimab, T-cell exhaustion and CAR-T persistence, Pemetrexed.
Shares Domvanalimab, Zimberelimab, T-cell exhaustion and CAR-T persistence, Paclitaxel / nab-paclitaxel.
Shares Domvanalimab, PD-L1-high non-small-cell lung cancer without a driver mutation, T-cell exhaustion and CAR-T persistence, Non-small-cell lung cancer.
Shares Pemetrexed, Paclitaxel / nab-paclitaxel, Carboplatin, Pembrolizumab.
Shares Pemetrexed, Paclitaxel / nab-paclitaxel, Carboplatin, Pembrolizumab.
Shares Arcus Biosciences, Domvanalimab, Zimberelimab, T-cell exhaustion and CAR-T persistence.
Shares Pemetrexed, Paclitaxel / nab-paclitaxel, Carboplatin, Pembrolizumab.
Shares T-cell exhaustion and CAR-T persistence, Pemetrexed, Carboplatin, Pembrolizumab.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/